Pangea Laboratory

Executive Summary

Pangea Laboratory is a San Diego-based CLIA-certified and CAP-accredited medical diagnostics company specializing in non-invasive testing and next-generation sequencing (NGS). Founded in 2019, the company partners with clinicians, researchers, and diagnostic developers to bring accurate, rapid, and reliable tests to market, with a primary focus on oncology and infectious diseases. Its proprietary Bladder CARE™ assay exemplifies its innovative approach to non-invasive detection of urological cancers. Operating in the rapidly growing precision diagnostics space, Pangea benefits from increasing demand for liquid biopsy and early detection solutions. However, as a private company with no disclosed funding or revenue, it faces intense competition from larger players. Its ability to differentiate through custom NGS services and expand its test menu will be critical to capturing market share.

Upcoming Catalysts (preview)

• Q1 2027Launch of next-generation Bladder CARE™ assay with expanded indications60% success
• Q4 2026Strategic partnership agreement with a major oncology pharmaceutical company40% success
• Q3 2026Publication of clinical validation data for a novel infectious disease diagnostic test50% success